KZR Valuation

Kezar Life Sciences Inc

Add to Watchlist

Advanced Chart

6.040

-0.01(-0.165%)1D

KZR Relative Valuation

KZR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KZR is overvalued; if below, it's undervalued.

Historical Valuation

Kezar Life Sciences Inc (KZR) is now in the Fair zone, suggesting that its current forward PS ratio of 6.05 is considered Fairly compared with the five-year average of -3.87. The fair price of Kezar Life Sciences Inc (KZR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：6.04

Fair

-1.08

Trailing

Forward

0.00

EV/EBITDA

Kezar Life Sciences Inc. (KZR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.76

EV/EBIT

Kezar Life Sciences Inc. (KZR) has a current EV/EBIT of 0.76. The 5-year average EV/EBIT is -1.24. The thresholds are as follows: Strongly Undervalued below -7.08, Undervalued between -7.08 and -4.16, Fairly Valued between 1.67 and -4.16, Overvalued between 1.67 and 4.59, and Strongly Overvalued above 4.59. The current Forward EV/EBIT of 0.76 falls within the Historic Trend Line -Fairly Valued range.

6.04

Kezar Life Sciences Inc. (KZR) has a current PS of 6.04. The 5-year average PS is 8.34. The thresholds are as follows: Strongly Undervalued below -23.30, Undervalued between -23.30 and -7.48, Fairly Valued between 24.15 and -7.48, Overvalued between 24.15 and 39.97, and Strongly Overvalued above 39.97. The current Forward PS of 6.04 falls within the Historic Trend Line -Fairly Valued range.

-1.82

P/OCF

Kezar Life Sciences Inc. (KZR) has a current P/OCF of -1.82. The 5-year average P/OCF is -3.55. The thresholds are as follows: Strongly Undervalued below -11.82, Undervalued between -11.82 and -7.68, Fairly Valued between 0.59 and -7.68, Overvalued between 0.59 and 4.72, and Strongly Overvalued above 4.72. The current Forward P/OCF of -1.82 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Kezar Life Sciences Inc. (KZR) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Kezar Life Sciences Inc (KZR) has a current Price-to-Book (P/B) ratio of 0.48. Compared to its 3-year average P/B ratio of 0.55 , the current P/B ratio is approximately -12.01% higher. Relative to its 5-year average P/B ratio of 1.40, the current P/B ratio is about -65.58% higher. Kezar Life Sciences Inc (KZR) has a Forward Free Cash Flow (FCF) yield of approximately -1.40%. Compared to its 3-year average FCF yield of -127.04%, the current FCF yield is approximately -98.89% lower. Relative to its 5-year average FCF yield of -80.12% , the current FCF yield is about -98.25% lower.

0.48

P/B

Median3y

0.55

Median5y

1.40

-1.45

FCF Yield

Median3y

-127.04

Median5y

-80.12

Competitors Valuation Multiple

The average P/S ratio for KZR's competitors is 4.16, providing a benchmark for relative valuation. Kezar Life Sciences Inc Corp (KZR) exhibits a P/S ratio of 6.04, which is 45.25% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KZR.O

Kezar Life Sciences Inc

Tvardi Therapeutics Inc

Mersana Therapeutics Inc

Performance Decomposition

Market capitalization of KZR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KZR in the past 1 year is driven by Unknown.